Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Stoke will receive $165m upfront from Biogen upon completion of the transaction. The company is eligible for up to $385m in development and commercial milestone payments, plus tiered royalties on ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), ...

Stoke could get up to $385 million in development and commercial milestone payments, plus potential tiered royalties on zorevunersen sales in Biogen’s territory. Biogen will support zorevunersen ...

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

Biogen's development organization had another ... Fourth quarter non-GAAP core operating expense or R&D plus SG&A expense increased 4% year-over-year, as the benefits from our R&D prioritization ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US. Dravet syndrome ...

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological diseases ...